Use of LDH and autoimmune side effects to predict response to ipilimumab treatment

被引：44

作者：

Dick, J. ^{[1
]}

Lang, N. ^{[1
]}

Slynko, A. ^{[2
]}

Kopp-Schneider, A. ^{[2
]}

Schulz, C. ^{[1
]}

Dimitrakopoulou-Strauss, A. ^{[3
]}

Enk, A. H. ^{[1
]}

Hassel, J. C. ^{[1
]}

机构：

[1] Univ Heidelberg Hosp, Dept Dermatol Natl Ctr Tumor Dis, Heidelberg, Germany

[2] German Canc Res Ctr, Dept Biostat, Heidelberg, Germany

[3] German Canc Res Ctr Heidelberg, Clin Cooperat Unit Nucl Med, Heidelberg, Germany

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 09期

关键词：

autoimmune side effects; ipilimumab; LDH; melanoma; EXPANDED ACCESS PROGRAM; METASTATIC MELANOMA; CTLA-4; BLOCKADE; CLINICAL-RESPONSE; SURVIVAL; EXPERIENCE; LYMPHOCYTE; THERAPY; IL-2;

D O I：

10.2217/imt-2016-0083

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. Methods: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data. Results: A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p <= 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit. Conclusion: Changes in LDH level and side effects correlate with response to therapy and survival.

引用

页码：1033 / 1044

页数：12

共 26 条

[1] ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].

ANDERSON, JR ;

CAIN, KC ;

GELBER, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719

[2] Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort [J].

Ascierto, Paolo A. ;

Simeone, Ester ;

Sileni, Vanna Chiarion ;

Pigozzo, Jacopo ;

Maio, Michele ;

Altomonte, Maresa ;

Del Vecchio, Michele ;

Di Guardo, Lorenza ;

Marchetti, Paolo ;

Ridolfi, Ruggero ;

Cognetti, Francesco ;

Testori, Alessandro ;

Bernengo, Maria Grazia ;

Guida, Michele ;

Marconcini, Riccardo ;

Mandala, Mario ;

Cimminiello, Carolina ;

Rinaldi, Gaetana ;

Aglietta, Massimo ;

Queirolo, Paola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[3] Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types [J].

Ascierto, Paolo A. ;

Kalos, Michael ;

Schaer, David A. ;

Callahan, Margaret K. ;

Wolchok, Jedd D. .

CLINICAL CANCER RESEARCH, 2013, 19 (05) :1009-1020

[4] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[5] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[6] Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival [J].

Delyon, J. ;

Mateus, C. ;

Lefeuvre, D. ;

Lanoy, E. ;

Zitvogel, L. ;

Chaput, N. ;

Roy, S. ;

Eggermont, A. M. M. ;

Routier, E. ;

Robert, C. .

ANNALS OF ONCOLOGY, 2013, 24 (06) :1697-1703

[7]

Eigentler TK, 2014, J IMMUNOTHER, V37, P374, DOI 10.1097/CJI.0000000000000046

[8] Melanoma Survival Disadvantage in Young, Non-Hispanic White Males Compared With Females [J].

Gamba, Christina S. ;

Clarke, Christina A. ;

Keegan, Theresa H. M. ;

Tao, Li ;

Swetter, Susan M. .

JAMA DERMATOLOGY, 2013, 149 (08) :912-920

[9] Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy [J].

Halama, Niels ;

Michel, Sara ;

Kloor, Matthias ;

Zoernig, Inka ;

Benner, Axel ;

Spille, Anna ;

Pommerencke, Thora ;

Doeberitz, Magnus von Knebel ;

Folprecht, Gunnar ;

Luber, Birgit ;

Feyen, Nadine ;

Martens, Uwe M. ;

Beckhove, Philipp ;

Gnjatic, Sacha ;

Schirmacher, Peter ;

Herpel, Esther ;

Weitz, Juergen ;

Grabe, Niels ;

Jaeger, Dirk .

CANCER RESEARCH, 2011, 71 (17) :5670-5677

[10]

Hannani D, 2015, CELL RES, V25, P399, DOI [10.1038/cr.2015.3, 10.1038/cr.2015.28]

← 1 2 3 →